DDInter489 DDInter1657
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Deferiprone {u} (Compound) binds {v} (Gene) UGT1A6
Deferiprone {u} (Compound) upregulates {v} (Gene) BTK
Deferiprone {u} (Compound) is included by {v} (Pharmacologic Class) Iron Chelating Activity
Deferiprone {u} (Compound) downregulates {v} (Gene) HSPA8
Deferiprone {u} (Compound) causes {v} (Side Effect) Rash pustular
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium sulfate
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Deferiprone (Compound) binds UGT1A6 (Gene)
Deferiprone (Compound) upregulates BTK (Gene)
Deferiprone (Compound) is included by Iron Chelating Activity (Pharmacologic Class)
Deferiprone (Compound) downregulates HSPA8 (Gene)
Deferiprone (Compound) causes Rash pustular (Side Effect)
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Deferiprone may lead to a major life threatening interaction when taken with Tioguanine
Deferiprone may lead to a major life threatening interaction when taken with Rucaparib